Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Sarcoma 1Melanoma 1Glioma 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cisplatin 17pembrolizumab 12Radiotherapy 11Nivolumab 7Cetuximab 6Paclitaxel 5fludarabine 4aldesleukin 4Radiation 4Interleukin-2 4Docetaxel 4Cyclophosphamide 4olaparib 3fludarabine phosphate 3Carboplatin 3talimogene laherparepvec 2atezolizumab 2Taxes 2Sorafenib 2Fluorouracil 2Erlotinib Hydrochloride 2Drug Therapy 2Capecitabine 2Bortezomib 2130-nm albumin-bound paclitaxel 2vandetanib 1tozuleristide 1tilsotolimod 1testosterone enanthate 1temoporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Squamous Cell × tozuleristide × Clear all
NCT02097875 2015-04-21

Safety Study of a Fluorescent Marker to Visualize Cancer Cells

Blaze Bioscience Australia Pty Ltd

Phase 1 Completed
21 enrolled
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡